CSL Seqirus Presents Real-World Evidence At OPTIONS XII Conference Highlighting Effectiveness Of Influenza Vaccinations
Results from real-world evidence (RWE) studies to be presented at OPTIONS XII show the effectiveness of cell-based and MF59® adjuva ...
Le Lézard30m
Maropost breaks records in G2 Fall 2024 Reports
Building on its G2 Summer Reports success, Maropost Marketing Cloud shattered records in G2's Fall 2024 Reports, securing an unprecedented 17 badges across 70 categories. G2, the world's largest ...
Le Lézard33m
Newterra Expands Wastewater Treatment Footprint in Texas
Newterra is excited to announce the expansion of its wastewater treatment plant (WWTP) footprint into Texas, marking a significant step in promoting sustainable water management practices. This ...
PipelineReview.com55m
Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination
Head-to-head data, presented at OPTIONS XII for the Control of Influenza Conference, demonstrates advantage of sa-mRNA over conventional mRNA in duration of ...
gastroenterologyadvisor20m
MF59-Adjuvanted Trivalent Influenza Vaccine Favored Among High-Risk Older Adults
The aTIV vaccine provides better protection against influenza-related medical encounters than the HD-TIV vaccine in high-risk older adults.